表达SARS-CoV-2刺突蛋白的重组新城疫病毒肌内接种保护hACE-2转基因小鼠抵抗SARS-CoV-2感染
本研究开发了表达SARS-CoV-2刺突蛋白的重组新城疫病毒载体疫苗rK148/beta-S,并在K18-hACE-2转基因小鼠中评估其效力。低剂量(10^6.0 EID50)肌内接种对SARS-CoV-2 beta变异株致死攻击提供76%存活率;高剂量(10^7.0 EID50)接种对beta和delta变异株攻击均显示100%存活率并降低肺部病毒载量。作者认为rK148/beta-S是一种可及且成本效益好的SARS-CoV-2疫苗。
要点
- 低剂量(10^6.0 EID50)rK148/beta-S对beta变异株致死攻击的存活率为76%。
- 高剂量(10^7.0 EID50)接种对beta和delta变异株攻击均达100%存活率并降低肺部病毒载量。
- 作者认为rK148/beta-S是一种可及且成本效益好的SARS-CoV-2疫苗。
核心结论
- 作者认为rK148/beta-S是一种可及且成本效益好的SARS-CoV-2疫苗。
研究设计与样本
- 本研究开发了表达SARS-CoV-2刺突蛋白的重组新城疫病毒载体疫苗rK148/beta-S,并在K18-hACE-2转基因小鼠中评估其效力。
主要发现
- 低剂量(10^6.0 EID50)肌内接种对SARS-CoV-2 beta(B.1.351)变异株致死攻击提供76%存活率。
- 高剂量(10^7.0 EID50)接种对beta和delta(B.1.617.2)变异株攻击均显示100%存活率并降低肺部病毒载量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronavirus disease 2019 (Covid-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) became a pandemic, causing significant burden on public health worldwide. Although the timely development and production of mRNA and adenoviral vector vaccines against SARS-CoV-2 have been successful, issues still exist in vaccine platforms for wide use and production. With the potential for proliferative capability and heat stability, the Newcastle disease virus (NDV)-vectored vaccine is a highly economical and conceivable candidate for treating emerging diseases. In this study, a recombinant NDV-vectored vaccine expressing the spike (S) protein of SARS-CoV-2, rK148/beta-S, was developed and evaluated for its efficacy against SARS-CoV-2 in K18-hACE-2 transgenic mice. Intramuscular vaccination with low dose (106.0 EID50) conferred a survival rate of 76 % after lethal challenge of a SARS-CoV-2 beta (B.1.351) variant. When administered with a high dose (107.0 EID50), vaccinated mice exhibited 100 % survival rate and reduced lung viral load against both beta and delta variants (B.1.617.2). Together with the protective immunity, rK148/beta-S is an accessible and cost-effective SARS-CoV-2 vaccine.
引用
- Kim DH, Lee J, Youk S, et al. Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection. Vaccine. 2023. PMID: 37355454. doi:10.1016/j.vaccine.2023.05.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。